SARS-CoV-2 B.1.617.2 Delta variant replication and imm

Nature

599, 114-119

DOI: 10.1038/s41586-021-03944-y

Citation Report

#	Article	IF	Citations
1	Rapid inactivation of SARS-CoV-2 by titanium dioxide surface coating. Wellcome Open Research, 2021, 6, 56.	0.9	7
4	Will SARS-CoV-2 variants of concern affect the promise of vaccines?. Nature Reviews Immunology, 2021, 21, 340-341.	10.6	162
5	SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology, 2021, 19, 409-424.	13.6	2,650
9	A SARS-CoV-2 mutant from B.1.258 lineage with âˆ†H69/âˆ†V70 deletion in the Spike protein circulating in Central Europe in the fall 2020. Virus Genes, 2021, 57, 556-560.	0.7	27
12	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778
14	Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021. Eurosurveillance, 2021, 26, .	3.9	46
15	Rapid inactivation of SARS-CoV-2 by titanium dioxide surface coating. Wellcome Open Research, 2021, 6, 56.	0.9	28
16	Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. Biochemical and Biophysical Research Communications, 2021, 574, 14-19.	1.0	70
17	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. Journal of Biological Chemistry, 2021, 297, 101151.	1.6	42
18	The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. Journal of Molecular Biology, 2022, 434, 167280.	2.0	92
19	Delta variant and black fungal invasion: A bidirectional assault might worsen the massive second/third stream of COVID-19 outbreak in South-Asia. Ethics, Medicine and Public Health, 2021, 19, 100722.	0.5	21
21	Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. Zoological Research, 2021, 42, 789-791.	0.9	28
22	N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains. Computational and Structural Biotechnology Journal, 2021, 19, 5556-5567.	1.9	39
23	SARS-CoV-2 Variants of Concern. Yonsei Medical Journal, 2021, 62, 961.	0.9	183
24	A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC. Vaccines, 2021, 9, 1106.	2.1	5
27	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2022, 28, 202-221.	2.8	569
28	Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains. Cellular and Molecular Immunology, 2021, 18, 2560-2562.	4.8	11
30	COVID-19: State of the Vaccination. Drugs and Therapy Perspectives, 2021, 37, 508-518.	0.3	5

#	Article	IF	Citations
33	Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science, 2021, 374, 995-999.	6.0	230
37	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines, 2021, 9, 1195.	2.1	90
39	Waning immunity to SARS-CoV-2: implications for vaccine booster strategies. Lancet Respiratory Medicine,the, 2021, 9, 1356-1358.	5.2	35
41	In Vitro Effect of Taraxacum officinale Leaf Aqueous Extract on the Interaction between ACE2 Cell Surface Receptor and SARS-CoV-2 Spike Protein D614 and Four Mutants. Pharmaceuticals, 2021, 14, 1055.	1.7	13
47	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science, 2021, 374, 1353-1360.	6.0	246
48	RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity. Water Research, 2021, 207, 117808.	5.3	39
50	Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation. Briefings in Bioinformatics, 2022, 23, .	3.2	17
51	Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. Frontiers in Immunology, 2021, 12, 742167.	2.2	32
53	Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland. Vaccines, 2021, 9, 1286.	2.1	117
54	Circulation and Evolution of SARS-CoV-2 in India: Let the Data Speak. Viruses, 2021, 13, 2238.	1.5	8
55	Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations. Scientific Reports, 2021, 11, 21735.	1.6	11
57	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. SSRN Electronic Journal, 0, , .	0.4	4
58	Highly sensitive and specific detection of the SARS-CoV-2 Delta variant by double-mismatch allele-specific real time reverse transcription PCR. Journal of Clinical Virology, 2022, 146, 105049.	1.6	15
59	Emergence of SARS-CoV-2 Delta Variant, Benin, Mayâ€“July 2021. Emerging Infectious Diseases, 2022, 28, 205-209.	2.0	4
62	Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatology, The, 2022, 4, e42-e52.	2.2	66
63	Kinetics of <scp>antiâ€SARSâ€CoV</scp>â€2 neutralizing antibodies development after <scp>BNT162b2</scp> vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	2.0	5
65	Limited Impact of Delta Variantâ€™s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population. Viruses, 2021, 13, 2405.	1.5	3
68	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	2.7	72

#	Article	IF	Citations
69	A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature, 2022, 601, 617-622.	13.7	153
70	Why are some coronavirus variants more infectious?. Journal of Biosciences, 2021, 46, 1.	0.5	18
72	Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host and Microbe, 2021, 29, 1788-1801.e6.	5.1	145
73	Neurological pathophysiology of SARSâ€CoVâ€2 and pandemic potential RNA viruses: a comparative analysis. FEBS Letters, 2021, 595, 2854-2871.	1.3	13
74	Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring. Communications Biology, 2021, 4, 1343.	2.0	27
75	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Research, 2021, 81, 6273-6280.	0.4	30
76	COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly. Vaccines, 2021, 9, 1299.	2.1	58
77	Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature, 2022, 602, 300-306.	13.7	428
78	COVID-19 vaccines in the age of the delta variant. Lancet Infectious Diseases, The, 2022, 22, 429-430.	4.6	6
81	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	13.5	64
82	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. Human Vaccines and Immunotherapeutics, 2024, 17, 4714-4740.	1.4	16
83	Vaccine third dose and cancer patients: necessity or luxury?. ESMO Open, 2021, 6, 100306.	2.0	9
84	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. ACS Infectious Diseases, 2022, 8, 29-58.	1.8	32
85	SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. IScience, 2021, 24, 103467.	1.9	26
86	mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant. SSRN Electronic Journal, 0, , .	0.4	34
87	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale, 2022, 14, 1054-1074.	2.8	22
88	Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles. Biosafety and Health, 2022, 4, 38-44.	1.2	7
90	Iron dysregulation in COVIDâ€19 and reciprocal evolution of SARSâ€CoVâ€2: Natura nihil frustra facit. Journal of Cellular Biochemistry, 2022, 123, 601-619.	1.2	21

#	Article	IF	Citations
91	Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India. Archives of Virology, 2022, 167, 393-403.	0.9	5
93	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. Applied Sciences (Switzerland), 2022, 12, 665.	1.3	8
95	The benefits, costs and feasibility of a low incidence COVID-19 strategy. Lancet Regional Health - Europe, The, 2022, 13, 100294.	3.0	17
96	A Simple Model to Estimate the Transmissibility of SARS-COV-2 Beta, Delta and Omicron Variants in South Africa. SSRN Electronic Journal, 0, , .	0.4	4
98	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nature Medicine, 2022, 28, 496-503.	15.2	215
99	Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598.	13.7	216
100	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature, 2022, 603, 693-699.	13.7	460
104	Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections. JCI Insight, 2022, 7, .	2.3	46
105	Saliva Quantification of SARS-CoV-2 in Real-Time PCR From Asymptomatic or Mild COVID-19 Adults. Frontiers in Microbiology, 2021, 12, 786042.	1.5	13
106	Innovative vaccine approachesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	1.8	5
108	Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes and Infections, 2022, 11, 477-481.	3.0	104
111	Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature, 2022, 603, 919-925.	13.7	146
114	Competitive Endogenous RNA Network Activates Host Immune Response in SARS-CoV-2-, panH1N1 (A/California/07/2009)-, and H7N9 (A/Shanghai/1/2013)-Infected Cells. Cells, 2022, 11, 487.	1.8	5
115	The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. Cell Reports, 2022, 38, 110218.	2.9	148
116	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
117	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell, 2022, 185, 872-880.e3.	13.5	165
118	Systemic corticosteroids for COVIDâ€19. Academic Emergency Medicine, 2021, , .	0.8	0
120	Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. BMC Medicine, 2022, 20, 29.	2.3	20

#	Article	IF	Citations
122	Nanoagent-based theranostic strategies against human coronaviruses. Nano Research, 2022, 15, 1-15.	5.8	4
123	Identification of SARS-CoV-2 Variants and Their Clinical Significance in Hefei, China. Frontiers in Medicine, 2021, 8, 784632.	1.2	9
127	Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?. Life, 2022, 12, 194.	1.1	25
128	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science, 2022, 375, 449-454.	6.0	108
129	mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell, 2022, 185, 457-466.e4.	13.5	881
130	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. Cell Host and Microbe, 2022, 30, 373-387.e7.	5.1	138
131	No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2. Cellular and Molecular Immunology, 2022, 19, 449-452.	4.8	7
133	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. Frontiers in Medicine, 2021, 8, 836826.	1.2	15
134	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. Frontiers in Cellular and Infection Microbiology, 2021, 11, 781429.	1.8	154
135	The effectiveness of mRNAâ€1273 vaccine against COVIDâ€19 caused by Delta variant: A systematic review and metaâ€analysis. Journal of Medical Virology, 2022, 94, 2269-2274.	2.5	14
136	Are convalescent plasma stocks collected during former COVIDâ€19 waves still effective against current <scp>SARSâ€CoV</scp>â€2 variants?. Vox Sanguinis, 2022, 117, 641-646.	0.7	8
137	Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern. Current Research in Virological Science, 2022, 3, 100019.	1.8	20
138	Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice. Journal of Virology, 2022, 96, jvi0218421.	1.5	14
139	Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants. MAbs, 2022, 14, 2021601.	2.6	11
140	SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell, 2022, 185, 847-859.e11.	13.5	590
141	Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell, 2022, 185, 630-640.e10.	13.5	358
142	Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell, 2022, 185, 860-871.e13.	13.5	310
143	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host and Microbe, 2022, 30, 154-162.e5.	5.1	153

#	Article	IF	Citations
144	mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annual Review of Medicine, 2022, 73, 17-39.	5.0	120
145	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 0, , .	13.7	61
148	Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. Journal of Hematology and Oncology, 2022, 15, 3.	6.9	28
149	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2022, 23, 835.	1.8	15
150	Decreased memory B cell frequencies in COVIDâ€19 delta variant vaccine breakthrough infection. EMBO Molecular Medicine, 2022, 14, e15227.	3.3	31
152	Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. Frontiers in Immunology, 2021, 12, 830527.	2.2	165
154	Rapid and sensitive identification of omicron by variant-specific PCR and nanopore sequencing: paradigm for diagnostics of emerging SARS-CoV-2 variants. Medical Microbiology and Immunology, 2022, 211, 71-77.	2.6	25
155	Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development. Journal of Molecular Biology, 2022, 434, 167438.	2.0	7
156	In vitro neutralizing activity of BNT162b2 mRNAâ€induced antibodies against full B.1.351 SARSâ€CoVâ€2 variant. Transboundary and Emerging Diseases, 2022, 69, 2649-2655.	1.3	1
158	Parental coronavirus disease vaccine hesitancy for children in Bangladesh: a cross-sectional study. F1000Research, 2022, 11, 90.	0.8	22
159	<scp>SARSâ€CoV</scp>â€2 Delta variant in Cartagena de Indias, Colombia, August 2021. Health Science Reports, 2022, 5, e480.	0.6	0
161	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 2022, 603, 679-686.	13.7	1,210
162	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. New England Journal of Medicine, 2022, 386, 951-963.	13.9	102
163	Realizing the Potential of Antiâ€“SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management. JAMA - Journal of the American Medical Association, 2022, 327, 427.	3.8	16
164	An exploratory study on the propagation of SARSâ€CoVâ€2 variants: Omicron is the most predominant variant. Journal of Medical Virology, 2022, 94, 2414-2421.	2.5	16
165	Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants. Research, 2022, 2022, 9781758.	2.8	15
166	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. Infectious Disease Clinics of North America, 2022, 36, 267-293.	1.9	10
167	SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature, 2022, 603, 715-720.	13.7	577

#	Article	IF	Citations
168	Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature, 2022, 603, 700-705.	13.7	447
170	Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovineâ€"Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019. Journal of Infectious Diseases, 2022, 226, 655-663.	1.9	4
171	Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. EBioMedicine, 2022, 76, 103818.	2.7	14
172	Human Organoids and Organsâ€onâ€Chips for Addressing COVIDâ€19 Challenges. Advanced Science, 2022, 9, e2105187.	5.6	19
173	Safe university: a guide for open academic institutions through the pandemic. Clinical Microbiology and Infection, 2022, 28, 634-636.	2.8	2
174	Transmission models indicate Ebola virus persistence in non-human primate populations is unlikely. Journal of the Royal Society Interface, 2022, 19, 20210638.	1.5	5
175	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature, 2022, 603, 706-714.	13.7	756
176	Reconstructing viral haplotypes using long reads. Bioinformatics, 2022, 38, 2127-2134.	1.8	4
177	Omicron (B.1.1.529) variant of SARSâ€CoVâ€2: Concerns, challenges, and recent updates. Journal of Medical Virology, 2022, 94, 2336-2342.	2.5	75
179	Points to consider for COVID-19 vaccine quality control and national lot release in Republic of Korea: focus on a viral vector platform. Osong Public Health and Research Perspectives, 2022, 13, 4-14.	0.7	0
181	Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up. Viruses, 2022, 14, 312.	1.5	19
182	Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2. Frontiers in Medicine, 2022, 9, 811004.	1.2	3
183	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2022, 399, 665-676.	6.3	280
185	SARS-CoV-2 Variants and Vaccination. Zoonoses, 2022, 2, .	0.5	16
186	SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021. MBio, 2022, 13, e0378821.	1.8	11
187	Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load. Viruses, 2022, 14, 323.	1.5	13
188	A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection. PLoS Pathogens, 2022, 18, e1010265.	2.1	28
189	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS ONE, 2022, 17, e0263328.	1.1	21

#	Article	IF	Citations
190	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. PLoS Pathogens, 2022, 18, e1010248.	2.1	48
191	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Signal Transduction and Targeted Therapy, 2022, 7, 42.	7.1	25
193	Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai. International Journal of Clinical Practice, 2022, 2022, 1-9.	0.8	0
194	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. Current Microbiology, 2022, 79, 20.	1.0	48
195	RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. Journal of Infection, 2022, 84, 579-613.	1.7	9
196	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	13.7	101
197	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 0, , .	13.7	72
198	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670.	13.7	917
199	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 2022, 602, 676-681.	13.7	1,038
200	Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study. Clinical Infectious Diseases, 2022, 75, e683-e691.	2.9	48
201	Transmission Dynamics of the Delta Variant of SARS-CoV-2 Infections in South Korea. Journal of Infectious Diseases, 2022, 225, 793-799.	1.9	47
219	COVID-19 vaccine breakthrough infections. Science, 2021, 374, 1561-1562.	6.0	81
220	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science, 2021, 374, 1621-1626.	6.0	232
221	Biparatopic nanobodies protect mice from lethal challenge with SARSâ€CoVâ€2 variants of concern. EMBO Reports, 2022, 23, e53865.	2.0	18
222	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. Viruses, 2021, 13, 2485.	1.5	23
223	Why are some coronavirus variants more infectious?. Journal of Biosciences, 2021, 46, .	0.5	2
224	Blocking key mutated hotspot residues in the RBD of the omicron variant (B.1.1.529) with medicinal compounds to disrupt the RBD-hACE2 complex using molecular screening and simulation approaches. RSC Advances, 2022, 12, 7318-7327.	1.7	20
225	The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia. Virus Evolution, 2022, 8, veac017.	2.2	24

#	Article	IF	Citations
226	Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opinion on Investigational Drugs, 2022, 31, 41-58.	1.9	26
228	Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection. Journal of Infectious Diseases, 2022, 226, 1204-1214.	1.9	30
229	SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. Microbiology Spectrum, 2022, 10, e0226221.	1.2	5
230	Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil. Microbiology Spectrum, 2022, 10, e0236621.	1.2	28
232	COVID-19 Vaccine: Between Myth and Truth. Vaccines, 2022, 10, 349.	2.1	12
234	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice. Npj Vaccines, 2022, 7, 23.	2.9	6
237	The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic. Frontiers in Immunology, 2022, 13, 833715.	2.2	7
238	Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate. Pharmaceuticals, 2022, 15, 258.	1.7	20
240	Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity. International Journal of Molecular Sciences, 2022, 23, 2643.	1.8	21
241	Organoid Studies in COVID-19 Research. International Journal of Stem Cells, 2022, 15, 3-13.	0.8	13
242	Exploring Noncovalent Protease Inhibitors for the Treatment of Severe Acute Respiratory Syndrome and Severe Acute Respiratory Syndrome-Like Coronaviruses. ACS Infectious Diseases, 2022, 8, 596-611.	1.8	6
244	Assessment of Mutations Associated With Genomic Variants of SARS-CoV-2: RT-qPCR as a Rapid and Affordable Tool to Monitoring Known Circulating Variants in Chile, 2021. Frontiers in Medicine, 2022, 9, 841073.	1.2	2
246	Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein. Biomedicines, 2022, 10, 441.	1.4	4
247	Delta Variant with P681R Critical Mutation Revealed by Ultra-Large Atomic-Scale Ab Initio Simulation: Implications for the Fundamentals of Biomolecular Interactions. Viruses, 2022, 14, 465.	1.5	11
248	Trained Immunity: An Overview and the Impact on COVID-19. Frontiers in Immunology, 2022, 13, 837524.	2.2	35
251	Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2. Vaccines, 2022, 10, 322.	2.1	8
252	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. Medical Review, 2022, 2, 3-22.	0.3	7
253	Mutations and Phylogenetic Analyses of SARS-CoV-2 Among Imported COVID-19 From Abroad in Nanjing, China. Frontiers in Microbiology, 2022, 13, 851323.	1.5	4

#	Article	IF	Citations
255	Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdropâ€"A Novel Perspective. International Journal of Diabetology, 2022, 3, 193-235.	0.9	6
257	Gauging the Impact of Artificial Intelligence and Mathematical Modeling in Response to the COVID-19 Pandemic: A Systematic Review. BioMed Research International, 2022, 2022, 1-28.	0.9	7
258	SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads. Cell Reports Medicine, 2022, 3, 100564.	3.3	61
259	The changing epidemiology of SARS-CoV-2. Science, 2022, 375, 1116-1121.	6.0	177
260	Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells. Virologica Sinica, 2022, 37, 380-389.	1.2	10
261	Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. Frontiers in Medical Technology, 2022, 4, 867982.	1.3	11
262	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. Frontiers in Immunology, 2022, 13, 836232.	2.2	15
263	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology, 2022, 19, 385-401.	12.5	135
264	The (apparent) antibody paradox in COVID-19. Expert Review of Clinical Immunology, 2022, 18, 335-345.	1.3	9
266	Targeting of neutrophil activation in the early phase of the disease for prevention of Coronavirus diseaseâ€19 severity. Microbiology and Immunology, 2022, 66, 264-276.	0.7	5
267	Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. Microbiology Spectrum, 2022, 10, e0225221.	1.2	9
269	Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant. Viruses, 2022, 14, 650.	1.5	10
270	Impact of the SARS-CoV-2 Delta Variant on the Psychological States and Health-Related Quality of Life in Patients With Crohnâ€™s Disease. Frontiers in Medicine, 2022, 9, 795889.	1.2	1
271	Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?. Organoids, 2022, 1, 2-27.	1.8	12
273	Massive third-wave COVID-19 outbreak in Bangladesh: aÂco-epidemic of dengue might worsen the situation. Future Virology, 2022, 17, 347-350.	0.9	7
274	Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. Cell Reports Medicine, 2022, 3, 100603.	3.3	27
275	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. ACS Infectious Diseases, 2022, 8, 825-840.	1.8	3
276	Coronavirus Genomes and Unique Mutations in Structural and Non-Structural Proteins in Pakistani SARS-CoV-2 Delta Variants during the Fourth Wave of the Pandemic. Genes, 2022, 13, 552.	1.0	13

#	Article	IF	Citations
278	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. EBioMedicine, 2022, 77, 103934.	2.7	10
280	ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern. Antiviral Research, 2022, 199, 105271.	1.9	13
281	Parental coronavirus disease vaccine hesitancy for children in Bangladesh: a cross-sectional study. F1000Research, 0, 11, 90.	0.8	5
282	RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection. Nature Communications, 2022, 13, 1444.	5.8	37
283	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. IScience, 2022, 25, 103939.	1.9	32
284	Post-pandemic COVID-19 estimated and forecasted hotspots in the Association of Southeast Asian Nations (ASEAN) countries in connection to vaccination rate. Geospatial Health, 2022, 17, .	0.3	2
285	SARS-CoV-2 variants, immune escape, and countermeasures. Frontiers of Medicine, 2022, 16, 196-207.	1.5	39
286	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Science Translational Medicine, 2022, 14, eabn8057.	5.8	150
288	Unvaccinated Children Are an Important Link in the Transmission of SARS-CoV-2 Delta Variant (B1.617.2): Comparative Clinical Evidence From a Recent Community Surge. Frontiers in Cellular and Infection Microbiology, 2022, 12, 814782.	1.8	9
289	SARS-CoV-2 spike E156G/Î”157-158 mutations contribute to increased infectivity and immune escape. Life Science Alliance, 2022, 5, e202201415.	1.3	24
293	Evolution of Responses to COVID-19 and Epidemiological Characteristics in South Korea. International Journal of Environmental Research and Public Health, 2022, 19, 4056.	1.2	11
294	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. Science Immunology, 2022, 7, eabo0226.	5.6	22
295	The vacciniaâ€based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses. Immunology and Cell Biology, 2022, 100, 250-266.	1.0	1
297	Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge. Npj Vaccines, 2022, 7, 36.	2.9	29
298	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. Frontiers in Immunology, 2022, 13, 773982.	2.2	10
299	The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year. Emerging Microbes and Infections, 2022, 11, 753-756.	3.0	7
300	SARSâ€CoVâ€2 and its variants of concern including Omicron: A never ending pandemic. Chemical Biology and Drug Design, 2022, 99, 769-788.	1.5	37
301	COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines. Inflammation Research, 2022, 71, 377-396.	1.6	11

#	Article	IF	Citations
302	A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. Emerging Microbes and Infections, 2022, 11, 914-925.	3.0	8
303	Specific Detection of SARS-CoV-2 Variants B.1.1.7 (Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay. Microbiology Spectrum, 2022, 10, e0217621.	1.2	9
304	Mass screening strategy for the SARS-CoV-2 delta variant outbreak in Guangzhou, May 2021. Clinical Microbiology and Infection, 2022, , .	2.8	1
305	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. Drug Design, Development and Therapy, 2022, Volume 16, 951-972.	2.0	4
306	Outcomes of COVID-19 in children with cancer â€“ Report from the Indian Pediatric Oncology Group (InPOG) COVID-19 registry in India. Pediatric Hematology Oncology Journal, 2022, , .	0.1	5
307	Comparative Analysis of SARS-CoV-2 Variants of Concern, Including Omicron, Highlights Their Common and Distinctive Amino Acid Substitution Patterns, Especially at the Spike ORF. Viruses, 2022, 14, 707.	1.5	30
309	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2â€“specific immune responses in rhesus macaques. Science Translational Medicine, 2022, 14, eabm4996.	5.8	13
311	Elucidating Design Principles for Engineering Cellâ€Derived Vesicles to Inhibit SARSâ€CoVâ€2 Infection. Small, 2022, 18, e2200125.	5.2	6
312	Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. Vaccines, 2022, 10, 557.	2.1	15
313	Molecular epidemiological features of SARS-CoV-2 in Japan, 2020â€“1. Virus Evolution, 2022, 8, veac034.	2.2	9
314	SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells. Cells, 2022, 11, 1262.	1.8	5
316	High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge. Nature Communications, 2022, 13, 1726.	5.8	5
317	Reassessing Reported Deaths and Estimated Infection Attack Rate during the First 6 Months of the COVID-19 Epidemic, Delhi, India. Emerging Infectious Diseases, 2022, 28, 759-766.	2.0	3
318	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell, 2022, 185, 1875-1887.e8.	13.5	148
319	First Detection of SARS-CoV-2 B.1.617.2 (Delta) Variant of Concern in a Symptomatic Cat in Spain. Frontiers in Veterinary Science, 2022, 9, 841430.	0.9	16
320	Human/SARS-CoV-2 genome-scale metabolic modeling to discover potential antiviral targets for COVID-19. Journal of the Taiwan Institute of Chemical Engineers, 2022, 133, 104273.	2.7	9
321	Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds. Drug Design, Development and Therapy, 2022, Volume 16, 1067-1082.	2.0	23
322	Dynamic Ca2+ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. Cell Reports, 2022, 39, 110694.	2.9	19

#	Article	IF	Citations
324	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. Npj Vaccines, 2022, 7, 41.	2.9	4
325	Unique peptide signatures of SARS-CÎ¿V-2 virus against human proteome reveal variantsâ€™ immune escape and infectiveness. Heliyon, 2022, 8, e09222.	1.4	2
326	Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia. International Journal of Molecular Sciences, 2022, 23, 4062.	1.8	8
328	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Microbiological Research, 2022, 258, 126993.	2.5	22
329	Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid. Computers in Biology and Medicine, 2022, 144, 105367.	3.9	21
330	Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabolism Open, 2022, 14, 100180.	1.4	41
331	The benefit of boosters: diversity and inclusion in the COVIDâ€19 memory response. Immunology and Cell Biology, 2022, 100, 15-17.	1.0	2
335	Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population. Vaccines, 2021, 9, 1459.	2.1	11
339	SARS-CoV-2 Variants: Mutations and Effective Changes. Biotechnology and Bioprocess Engineering, 2021, 26, 859-870.	1.4	12
340	Carbon Ion Radiotherapy Acts as the Optimal Treatment Strategy for Unresectable Liver Cancer During the Coronavirus Disease 2019 Crisis. Frontiers in Public Health, 2021, 9, 767617.	1.3	3
341	A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. Frontiers in Immunology, 2021, 12, 789905.	2.2	7
342	Broadâ€spectrum prodrugs with antiâ€SARSâ€CoVâ€2 activities: Strategies, benefits, and challenges. Journal of Medical Virology, 2022, 94, 1373-1390.	2.5	35
343	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. Journal of Developmental Biology, 2021, 9, 58.	0.9	27
344	SARS-CoV-2 spike engagement of ACE2 primes S2â€² site cleavage and fusion initiation. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	60
346	Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Frontiers in Immunology, 2021, 12, 795741.	2.2	13
347	Learning From Biological and Computational Machines: Importance of SARS-CoV-2 Genomic Surveillance, Mutations and Risk Stratification. Frontiers in Cellular and Infection Microbiology, 2021, 11, 783961.	1.8	2
349	Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature, 2022, 602, 487-495.	13.7	237
350	Estimating the strength of selection for new SARS-CoV-2 variants. Nature Communications, 2021, 12, 7239.	5.8	23

#	Article	IF	Citations
352	COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response. Biochem, 2022, 2, 115-144.	0.5	1
353	Breakthrough gastrointestinal COVID and intra-host evolution consequent to combination monoclonal antibody prophylaxis. Journal of Infectious Diseases, 2022, , .	1.9	0
354	Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients. Kidney International, 2022, 101, 1282-1286.	2.6	40
355	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	1.4	10
356	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. ACS Infectious Diseases, 2022, 8, 1253-1264.	1.8	20
357	SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. Cell Reports, 2022, 39, 110754.	2.9	5
358	The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan. MBio, 2022, 13, e0068322.	1.8	17
359	Importation of SARS-CoV-2 Omicron variant in Beijing, China. Biosafety and Health, 2022, 4, 150-153.	1.2	3
360	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. Vaccines, 2022, 10, 591.	2.1	27
363	Maternal and perinatal outcomes of <scp>SARSâ€CoV</scp>â€2 infection in unvaccinated pregnancies during Delta and Omicron waves. Ultrasound in Obstetrics and Gynecology, 2022, 60, 96-102.	0.9	38
365	Comparative analysis of SARS-CoV-2 quasispecies in the upper and lower respiratory tract shows an ongoing evolution in the spike cleavage site. Virus Research, 2022, 315, 198786.	1.1	5
366	Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology. Journal of Molecular Cell Biology, 2022, 14, .	1.5	4
367	Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability. Journal of Physical Chemistry B, 2022, 126, 2812-2823.	1.2	11
369	Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron. Journal of Infectious Diseases, 2022, 226, 1551-1555.	1.9	4
370	Risk of sustained SARS-CoV-2 transmission in Queensland, Australia. Scientific Reports, 2022, 12, 6309.	1.6	5
371	The Evolution and Biology of SARS-CoV-2 Variants. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a041390.	2.9	110
372	Evaluation of a Rapid and Accessible Reverse Transcription-Quantitative PCR Approach for SARS-CoV-2 Variant of Concern Identification. Journal of Clinical Microbiology, 2022, 60, e0017822.	1.8	15
373	Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies. Molecular Biomedicine, 2022, 3, 12.	1.7	12

#	Article	IF	Citations
374	Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics.. Acta Biomedica, 2022, 93, e2022179.	0.2	9
375	An Electrochemical Biosensor for SARS-CoV-2 Detection Via its Papain-Like Cysteine Protease and the Protease Inhibitor Screening. SSRN Electronic Journal, 0, , .	0.4	0
376	Long-read 16S-seq reveals nasopharynx microbial dysbiosis and enrichment of Mycobacterium and Mycoplasma in COVID-19 patients: a potential source of co-infection. Molecular Omics, 2022, 18, 490-505.	1.4	5
377	Croup as a Manifestation of SARS-CoV-2 Omicron Variant Infection in Young Children. Journal of Korean Medical Science, 2022, 37, .	1.1	17
378	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
379	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323.	2.2	24
380	Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virology Journal, 2022, 19, 76.	1.4	61
381	Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients. Viruses, 2022, 14, 882.	1.5	3
383	Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. Signal Transduction and Targeted Therapy, 2022, 7, 139.	7.1	14
384	Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. Cell Host and Microbe, 2022, 30, 1093-1102.e3.	5.1	114
386	Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration. Vaccines, 2022, 10, 690.	2.1	2
387	Clinical challenges of SARSâ€'CoVâ€'2 variants (Review). Experimental and Therapeutic Medicine, 2022, 23, .	0.8	12
388	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. Translational Research, 2022, 248, 11-21.	2.2	13
389	SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination. Microorganisms, 2022, 10, 857.	1.6	8
391	A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathogens, 2022, 18, e1010465.	2.1	8
392	Phylodynamic Dispersal of SARS-CoV-2 Lineages Circulating across Polishâ€"German Border Provinces. Viruses, 2022, 14, 884.	1.5	2
393	Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Reports, 2022, 39, 110829.	2.9	214
394	Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination. Frontiers in Immunology, 2022, 13, .	2.2	16

#	Article	IF	Citations
395	Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages. MSphere, 2022, 7, e0091321.	1.3	8
396	Epidemiological Characteristics of COVID-19 Outbreak in Yangzhou, China, 2021. Frontiers in Microbiology, 2022, 13, .	1.5	1
397	Unique Aggregation of Retroviral Particles Pseudotyped with the Delta Variant SARS-CoV-2 Spike Protein. Viruses, 2022, 14, 1024.	1.5	2
398	The role of children in household transmission of COVID-19: a systematic review and meta-analysis. International Journal of Infectious Diseases, 2022, 122, 266-275.	1.5	44
399	Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2. Expert Review of Clinical Immunology, 2022, 18, 557-565.	1.3	10
400	Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain. Journal of Molecular Biology, 2022, 434, 167622.	2.0	3
401	Comparative Analysis of Age, Sex, and Viral Load in Outpatients during the Four Waves of SARS-CoV-2 in A Mexican Medium-Sized City. International Journal of Environmental Research and Public Health, 2022, 19, 5719.	1.2	4
402	Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARSâ€CoVâ€2 Omicron BA.1 variant. MedComm, 2022, 3, e143.	3.1	3
403	SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells. Journal of Virology, 2022, 96, e0059422.	1.5	21
404	Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell, 2022, 185, 2103-2115.e19.	13.5	273
405	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. Molecular Therapy, 2022, 30, 2952-2967.	3.7	2
406	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
408	A SARS-CoV-2 Delta Variant Case Manifesting as Extensive Placental Infection and Fetal Transmission. Gynecologic and Obstetric Investigation, 2022, 87, 165-172.	0.7	11
410	When and which patients should receive remdesivir?. Lancet, The, 2022, 399, 1918-1920.	6.3	2
411	Breakthrough COVID-19 Infections in the US: Implications for Prolonging the Pandemic. Vaccines, 2022, 10, 755.	2.1	13
412	Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice. Journal of Immunological Methods, 2022, 506, 113279.	0.6	5
413	Investigation of the binding and dynamic features of A.30 variant revealed higher binding of RBD for hACE2 and escapes the neutralizing antibody: A molecular simulation approach. Computers in Biology and Medicine, 2022, 146, 105574.	3.9	4
414	Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022, 55, 925-944.	6.6	74

#	Article	IF	Citations
415	The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants. Science Translational Medicine, 2022, 14, eabm7621.	5.8	22
416	Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, 159.	7.1	21
417	How SARS-CoV-2 dodges immune surveillance and facilitates infection: an analytical review. Expert Review of Anti-Infective Therapy, 2022, 20, 1119-1127.	2.0	1
418	SARS-CoV-2 Kappa Variant Shows Pathogenicity in a Syrian Hamster Model. Vector-Borne and Zoonotic Diseases, 2022, 22, 289-296.	0.6	2
419	An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation. Journal of Molecular Biology, 2022, 434, 167637.	2.0	1
420	Is Omicron the end of pandemic or start of a new innings?. Travel Medicine and Infectious Disease, 2022, 48, 102332.	1.5	27
421	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. Indian Journal of Medical Research, 2022, 155, 105.	0.4	2
424	Whole-genome sequencing of SARS-CoV-2 reveals diverse mutations in circulating Alpha and Delta variants during the first, second, and third waves of COVID-19 in South Kivu, east of the Democratic Republic of the Congo. International Journal of Infectious Diseases, 2022, 122, 136-143.	1.5	14
427	A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding. Frontiers in Immunology, 2022, 13, .	2.2	7
429	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. Frontiers in Immunology, 2022, 13, .	2.2	37
430	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. Pharmaceutics, 2022, 14, 1101.	2.0	15
431	Incidence of SARS-CoV-2 over four epidemic waves in a low-resource community in Rio de Janeiro, Brazil: A prospective cohort study. The Lancet Regional Health Americas, 2022, 12, 100283.	1.5	8
434	Identifying COVID-19 Severity-Related SARS-CoV-2 Mutation Using a Machine Learning Method. Life, 2022, 12, 806.	1.1	11
436	Detection of SARS-CoV-2 Delta Variant of Concern AY.57 and Clinical Characteristics of Imported Cases on a Vietnamese Coal Carrier Vessel in East Kalimantan, Indonesia: A Case Report. Jurnal Respirasi, 2022, 8, 99-105.	0.1	0
437	Association of disease severity and death outcome with vaccination status of admitted COVID-19 patients in delta period of SARS-COV-2 in mixed variety of vaccine background. Saudi Journal of Biological Sciences, 2022, 29, 103329.	1.8	10
438	Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice. Virology Journal, 2022, 19, .	1.4	3
440	Geographical distribution of <scp>SARSâ€CoV</scp>â€2 amino acids mutations and the concomitant evolution of seven distinct clades in nonâ€human hosts. Zoonoses and Public Health, 2022, 69, 816-825.	0.9	4
441	Generation of Novel Severe Acute Respiratory Syndrome Coronavirus 2 Variants on the B.1.1.7 Lineage in 3 Patients With Advanced Human Immunodeficiency Virus-1 Disease. Clinical Infectious Diseases, 2022, 75, 2016-2018.	2.9	20

#	Article	IF	Citations
442	Leveraging South African <scp>HIV</scp> research to define <scp>SARSâ€CoV</scp>â€2 immunity triggered by sequential variants of concern. Immunological Reviews, 2022, 310, 61-75.	2.8	6
444	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. International Reviews of Immunology, 2023, 42, 393-414.	1.5	26
447	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nature Microbiology, 2022, 7, 896-908.	5.9	32
448	The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination. Vaccines, 2022, 10, 794.	2.1	5
450	Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Reports, 2022, 39, 110924.	2.9	20
451	In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Nucleocapsid Through Molecular Docking-Based Drug Repurposing. Dr Sulaiman Al Habib Medical Journal, 2022, 4, 64-76.	0.3	2
452	Dominance of Three Sublineages of the SARS-CoV-2 Delta Variant in Mexico. Viruses, 2022, 14, 1165.	1.5	12
453	Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice. Viruses, 2022, 14, 1139.	1.5	21
454	SARSâ€CoVâ€2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. Small, 2022, 18, .	5.2	11
455	SARS CoV-2 (Delta Variant) Infection Kinetics and Immunopathogenesis in Domestic Cats. Viruses, 2022, 14, 1207.	1.5	5
456	Recent insights into SARSâ€CoVâ€2 omicron variant. Reviews in Medical Virology, 2023, 33, .	3.9	29
457	Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19. Frontiers in Immunology, 0, 13, .	2.2	17
458	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. Clinical and Experimental Vaccine Research, 2022, 11, 173.	1.1	0
459	Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clinical and Experimental Vaccine Research, 2022, 11, 209.	1.1	4
461	Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (Juneâ€"July 2021). Vaccines, 2022, 10, 984.	2.1	10
462	Epidemic model with strain-dependent transmission rate. Communications in Nonlinear Science and Numerical Simulation, 2022, 114, 106641.	1.7	3
463	Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy. Journal of Biomedical Science, 2022, 29, .	2.6	4
466	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. Vaccines, 2022, 10, 919.	2.1	23

#	Article	IF	Citations
467	Understanding COVID-19 Vaccines Today: Are T-cells Key Players?. Vaccines, 2022, 10, 904.	2.1	7
468	Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination. Nature Communications, 2022, 13, .	5.8	11
469	The antiâ€“SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Science Translational Medicine, 2022, 14, .	5.8	19
471	The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3, .	1.2	24
474	Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19. ELife, 0, 11, .	2.8	2
475	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. Viruses, 2022, 14, 1232.	1.5	2
476	SARS-CoV-2: A Master of Immune Evasion. Biomedicines, 2022, 10, 1339.	1.4	24
477	COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant and implications for vaccination. Journal of the Royal Society Interface, 2022, 19, .	1.5	60
478	The association between social media use and hesitancy toward COVID-19 vaccine booster shots in China: A web-based cross-sectional survey. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	19
479	COVIDHunter: COVID-19 Pandemic Wave Prediction and Mitigation via Seasonality Aware Modeling. Frontiers in Public Health, 0, 10, .	1.3	2
481	Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021. Clinical Infectious Diseases, 2022, 75, S110-S120.	2.9	10
482	Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history. Genome Medicine, 2022, 14, .	3.6	15
483	The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs. Frontiers in Immunology, 0, 13, .	2.2	1
484	Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation. Scientific Reports, 2022, 12, .	1.6	12
485	Drivers of adaptive evolution during chronic SARS-CoV-2 infections. Nature Medicine, 2022, 28, 1501-1508.	15.2	81
486	Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. Science Immunology, 2022, 7, .	5.6	89
487	Exploring the risk factors of COVIDâ€19 Delta variant in the United States based on Bayesian spatioâ€temporal analysis. Transboundary and Emerging Diseases, 2022, 69, .	1.3	3
488	Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern. Frontiers in Immunology, 0, 13, .	2.2	7

#	Article	IF	Citations
489	Computational Investigations of Traditional Chinese Medicinal Compounds against the Omicron Variant of SARS-CoV-2 to Rescue the Host Immune System. Pharmaceuticals, 2022, 15, 741.	1.7	3
490	The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach. Microbial Pathogenesis, 2022, 169, 105619.	1.3	4
491	Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021. Vaccines, 2022, 10, 970.	2.1	6
492	Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases. Journal of Drug Delivery Science and Technology, 2022, 74, 103541.	1.4	7
493	Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins. International Journal of Molecular Sciences, 2022, 23, 6394.	1.8	17
494	Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers. Scientific Reports, 2022, 12, .	1.6	9
495	Rapid repeat infection of SARS-CoV-2 by two highly distinct delta-lineage viruses. Diagnostic Microbiology and Infectious Disease, 2022, 104, 115747.	0.8	3
496	RelCoVaxÂ®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice. Vaccine, 2022, 40, 4522-4530.	1.7	6
497	Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths. Journal of Personalized Medicine, 2022, 12, 995.	1.1	9
498	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. Viruses, 2022, 14, 1255.	1.5	30
499	COVID-19 Diagnosis: A Comprehensive Review of the RT-qPCR Method for Detection of SARS-CoV-2. Diagnostics, 2022, 12, 1503.	1.3	28
500	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Nature Communications, 2022, 13, .	5.8	22
501	From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1704-1714.	2.5	15
502	Production and characterization of chimeric SARS-CoV-2 antigens based on the capsid protein of cowpea chlorotic mottle virus. International Journal of Biological Macromolecules, 2022, 213, 1007-1017.	3.6	3
503	Immunogenicity and Safety of Homologous and Heterologous Booster Vaccination of ChAdOx1 nCoV-19 (COVISHIELD ^{TM}) and BBV152 (COVAXINÂ®) in Previous Recipients of COVISHIELD ^{TM} or COVAXINÂ®: A Phase 4, Participant and Observer Blinded, Randomised Study. SSRN Electronic Journal, 0, , .	0.4	1
504	Broadly Neutralizing Antibodies Against Omicron Variants of SARS-CoV-2 Derived from mRNA-Lipid Nanoparticle-Immunized Mice. SSRN Electronic Journal, 0, , .	0.4	0
505	SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern. SSRN Electronic Journal, 0, , .	0.4	3
506	Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees. Frontiers in Immunology, 0, 13, .	2.2	4

#	Article	IF	Citations
508	Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study. Vaccines, 2022, 10, 1050.	2.1	3
509	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	59
510	SARS-CoV-2 cell entry beyond the ACE2 receptor. Molecular Biology Reports, 2022, 49, 10715-10727.	1.0	29
511	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. PLoS Pathogens, 2022, 18, e1010592.	2.1	13
512	Detection of SARS-CoV-2 intra-host recombination during superinfection with Alpha and Epsilon variants in New York City. Nature Communications, 2022, 13, .	5.8	22
513	Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern. Nature Communications, 2022, 13, .	5.8	28
514	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	2.2	28
515	A broad and potent neutralization epitope in SARS-related coronaviruses. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	34
516	Antibodyâ€“nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants. Scientific Reports, 2022, 12, .	1.6	2
517	Epidemiological investigation of the COVID-19 outbreak in Vellore district in South India using Geographic Information Surveillance (GIS). International Journal of Infectious Diseases, 2022, 122, 669-675.	1.5	3
518	Attenuation of <scp>SARSâ€CoV</scp>â€2 replication and associated inflammation by concomitant targeting of viral and host cap 2'â€Oâ€ribose methyltransferases. EMBO Journal, 2022, 41, .	3.5	18
519	Raman Fingerprints of the SARS-CoV-2 Delta Variant and Mechanisms of Its Instantaneous Inactivation by Silicon Nitride Bioceramics. ACS Infectious Diseases, 2022, 8, 1563-1581.	1.8	7
522	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. International Journal of Molecular Sciences, 2022, 23, 7675.	1.8	9
523	Analysis of the docking property of host variants of hACE2 for SARS-CoV-2 in a large cohort. PLoS Computational Biology, 2022, 18, e1009834.	1.5	1
524	The Mutational Landscape of SARS-CoV-2 Variants of Concern Recovered From Egyptian Patients in 2021. Frontiers in Microbiology, 0, 13, .	1.5	1
525	Contact tracing of COVID-19 in Karnataka, India: Superspreading and determinants of infectiousness and symptomatic infection. PLoS ONE, 2022, 17, e0270789.	1.1	12
526	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. Communications Biology, 2022, 5, .	2.0	26
527	Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose. Emerging Infectious Diseases, 2022, 28, 1375-1383.	2.0	17

#	Article	IF	Citations
528	Fragment-based inhibitor design for SARS-CoV2 main protease. Structural Chemistry, 2022, 33, 1467-1487.	1.0	1
529	Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nature Communications, 2022, 13, .	5.8	53
530	The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. Clinical Microbiology and Infection, 2022, 28, 1636-1643.	2.8	3
531	A booster dose of Deltaâ€‰Ã—â€‰Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. Journal of Biomedical Science, 2022, 29, .	2.6	42
532	Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage. Frontiers in Pharmacology, 0, 13, .	1.6	0
533	COVID-19: Challenges of Viral Variants. Annual Review of Medicine, 2023, 74, 31-53.	5.0	43
535	SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production. IScience, 2022, 25, 104759.	1.9	11
536	Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nature Communications, 2022, 13, .	5.8	43
538	A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. Journal of Virology, 2022, 96, .	1.5	7
539	A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant. Journal of Virology, 2022, 96, .	1.5	2
540	Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nature Microbiology, 2022, 7, 1180-1188.	5.9	39
541	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. International Immunology, 2022, 34, 595-607.	1.8	19
542	Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape. Chinese Medical Journal, 0, Publish Ahead of Print, .	0.9	3
543	From Alpha to Deltaâ€”Genetic Epidemiology of SARS-CoV-2 (hCoV-19) in Southern Poland. Pathogens, 2022, 11, 780.	1.2	6
544	Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins. IScience, 2022, 25, 104722.	1.9	8
545	Ex situ-armus: experimental models for combating respiratory dysfunction. Current Opinion in Genetics and Development, 2022, 75, 101946.	1.5	1
546	Does the â€œDelta Variantâ€•affect the nonlinear dynamic characteristics of SARS-CoV-2 transmission?. Chaos, Solitons and Fractals, 2022, 162, 112382.	2.5	1
548	EpiRegress: A Method to Estimate and Predict the Time-Varying Effective Reproduction Number. Viruses, 2022, 14, 1576.	1.5	4

#	Article	IF	Citations
549	Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity. Acta Pharmaceutica Sinica B, 2023, 13, 2219-2233.	5.7	9
551	Dynamics in the Neurotrauma Catchment Area of a German University Hospital during the COVID-19 Pandemic. Healthcare (Switzerland), 2022, 10, 1376.	1.0	2
552	Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. Nature Chemical Biology, 2022, 18, 1056-1064.	3.9	26
553	Molecular characterization of SARS-CoV-2 detected in Tokyo, Japan during five waves: Identification of the amino acid substitutions associated with transmissibility and severity. Frontiers in Microbiology, 0, 13, .	1.5	7
554	SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection. Microbiology Spectrum, 2022, 10, .	1.2	8
555	Alveolar macrophages: Achillesâ€™ heel of SARS-CoV-2 infection. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	15
556	Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants. CheM, 2022, 8, 2766-2783.	5.8	18
557	Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science, 2022, 377, 890-894.	6.0	142
558	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. EBioMedicine, 2022, 82, 104141.	2.7	11
559	SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. Pathogens, 2022, 11, 837.	1.2	0
560	SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. Frontiers in Immunology, 0, 13, .	2.2	31
561	Inhibiting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants: Targeting the Spike and Envelope Proteins Using Nanomaterial Like Peptides. Journal of Biomedical Nanotechnology, 2022, 18, 1121-1130.	0.5	2
562	Nanomechanical analysis of SARS-CoV-2 variants and predictions of infectiousness and lethality. Soft Matter, 2022, 18, 5833-5842.	1.2	3
563	A Framework for Infectious Disease Monitoring With Automated Contact Tracingâ€”A Case Study of COVID-19. IEEE Internet of Things Journal, 2023, 10, 144-165.	5.5	5
564	A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine. MBio, 2022, 13, .	1.8	17
565	SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. Nature Communications, 2022, 13, .	5.8	24
567	Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia. Frontiers in Medicine, 0, 9, .	1.2	4
568	Sensitivity and Specificity of Patient-Reported Clinical Manifestations to Diagnose COVID-19 in Adults from a National Database in Chile: A Cross-Sectional Study. Biology, 2022, 11, 1136.	1.3	1

#	Article	IF	Citations
569	Replacement of the Alpha variant of SARS-CoV-2 by the Delta variant in Lebanon between April and June 2021. Microbial Genomics, 2022, 8, .	1.0	8
571	Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study. Breast Cancer Research and Treatment, 2022, 195, 311-323.	1.1	7
572	A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Journal of Virology, 2022, 96, .	1.5	15
573	Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines. Communications Medicine, 2022, 2, .	1.9	3
574	Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease. MBio, 0, , .	1.8	3
575	Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies. Communications Biology, 2022, 5, .	2.0	5
576	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. Frontiers in Immunology, 0, 13, .	2.2	4
577	Evolutionary remodelling of Nâ€terminal domain loops fineâ€tunes <scp>SARSâ€CoV</scp>â€2 spike. EMBO Reports, 2022, 23, .	2.0	18
578	Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. Cell Host and Microbe, 2022, 30, 1242-1254.e6.	5.1	27
579	Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. IScience, 2022, 25, 104914.	1.9	5
580	Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells. PLoS Biology, 2022, 20, e3001728.	2.6	15
581	Transmission Dynamics and Genomic Epidemiology of Emerging Variants of SARS-CoV-2 in Bangladesh. Tropical Medicine and Infectious Disease, 2022, 7, 197.	0.9	4
582	RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. MSphere, 2022, 7, .	1.3	8
583	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. Journal of Virology, 2022, 96, .	1.5	14
585	Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. Npj Vaccines, 2022, 7, .	2.9	68
586	Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study. Frontiers in Immunology, 0, 13, .	2.2	14
588	Context-specific emergence and growth of the SARS-CoV-2 Delta variant. Nature, 2022, 610, 154-160.	13.7	60
589	Cross-Border Transmissions of the Delta Substrain AY.29 During Tokyo Olympic and Paralympic Games. Frontiers in Microbiology, 0, 13, .	1.5	6

#	Article	IF	Citations
590	Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer. British Journal of Cancer, 2022, 127, 1787-1792.	2.9	3
591	SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity. Journal of Infectious Diseases, 2022, 227, 40-49.	1.9	6
592	Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the Saccharomyces cerevisiae cell surface. Frontiers in Immunology, 0, 13, .	2.2	3
593	Attitudes toward Receiving COVID-19 Booster Dose in the Middle East and North Africa (MENA) Region: A Cross-Sectional Study of 3041 Fully Vaccinated Participants. Vaccines, 2022, 10, 1270.	2.1	12
594	Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents. Communications Biology, 2022, 5, .	2.0	11
595	Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern. Scientific Reports, 2022, 12, .	1.6	26
596	Containing novel SARS-CoV-2 variants at source is possible with high-intensity sequencing. , 2022, 1, .		3
597	Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infectious Diseases, 2022, 8, 1758-1814.	1.8	47
598	Free energy perturbationâ€“based large-scale virtual screening for effective drug discovery against COVID-19. International Journal of High Performance Computing Applications, 0, , 109434202211177.	2.4	3
599	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nature Communications, 2022, 13, .	5.8	27
601	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nature Communications, 2022, 13, .	5.8	12
603	SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. Cell Reports, 2022, 40, 111220.	2.9	24
604	Neutralizing antibodies to SARSâ€CoVâ€2 variants of concern including Delta and Omicron in subjects receiving mRNAâ€1273, BNT162b2, and Ad26.COV2.S vaccines. Journal of Medical Virology, 2022, 94, 5678-5690.	2.5	16
605	Nanotechnology-based strategies against SARS-CoV-2 variants. Nature Nanotechnology, 2022, 17, 1027-1037.	15.6	63
606	Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. 3 Biotech, 2022, 12, .	1.1	4
607	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. IScience, 2022, 25, 104886.	1.9	5
608	Predicting COVID-19 disease severity from SARS-CoV-2 spike protein sequence by mixed effects machine learning. Computers in Biology and Medicine, 2022, 149, 105969.	3.9	7
609	Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study. Digestive Diseases and Sciences, 2023, 68, 676-684.	1.1	6

#	Article	IF	Citations
610	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. Cell Discovery, 2022, 8, .	3.1	13
611	Genomic surveillance of SARS-CoV-2 Omicron variants on a university campus. Nature Communications, 2022, 13, .	5.8	15
612	Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis. Vaccines, 2022, 10, 1572.	2.1	5
613	SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. EBioMedicine, 2022, 84, 104270.	2.7	86
614	Nonlinear optimal control strategies for a mathematical model of COVID-19 and influenza co-infection. Physica A: Statistical Mechanics and Its Applications, 2022, 607, 128173.	1.2	30
615	A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. Mathematical Biosciences and Engineering, 2022, 19, 10361-10373.	1.0	5
616	Spatial Epidemiology of COVID-19 Pandemic: Disease Risk, Prognosis, and Complications. , 2022, , 241-257.		1
617	A kinetic model considering the decline of antibody level and simulation about vaccination effect of COVID-19. Mathematical Biosciences and Engineering, 2022, 19, 12558-12580.	1.0	0
618	A computational evaluation of structural stability of omicron and delta mutations of SARS-CoV-2 spike proteins and human ACE-2 interactions. Informatics in Medicine Unlocked, 2022, 33, 101074.	1.9	2
619	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. International Journal of Biological Sciences, 2022, 18, 4781-4791.	2.6	5
620	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
621	Will New Variants Emerge after Delta and Omicron?. , 2022, 13, 1317.		1
622	Biophysical and structural characterizations of the effects of mutations on the structureâ€“activity relationships of SARS-CoV-2 spike protein. Methods in Enzymology, 2022, , 299-321.	0.4	2
623	Home Isolation and Online Support Strategies to Mild COVID-19 Epidemic Waves in Thailand: Preparing for the Next. SSRN Electronic Journal, 0, , .	0.4	0
624	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	1.1	12
625	COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments. Advances in Infectious Diseases, 2022, 12, 568-631.	0.0	1
626	Sports Participation and Anti-Epidemic: Empirical Evidence on the Influence of Regular Physical Activity on the COVID-19 Pandemic in Mainland China. International Journal of Environmental Research and Public Health, 2022, 19, 10689.	1.2	1
627	Third Early â€œBoosterâ€•Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. Viruses, 2022, 14, 1928.	1.5	5

#	Article	IF	Citations
628	Modelling airborne transmission of SARS-CoV-2 at a local scale. PLoS ONE, 2022, 17, e0273820.	1.1	3
629	Genomic characterization of SARS-CoV-2 from vaccine breakthrough cases in Allegheny County, Pennsylvania. PLoS ONE, 2022, 17, e0272954.	1.1	0
630	Simultaneous measurement of the antibody responses against SARS-CoV-2 and its multiple variants by a phage display mediated immuno-multiplex quantitative PCR-based assay. Frontiers in Microbiology, 0, 13, .	1.5	3
632	Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. Frontiers in Immunology, 0, 13, .	2.2	2
633	Low rate of SARS-CoV-2 incident infection identified by weekly screening PCR in a prospective year-long cohort study. PLoS ONE, 2022, 17, e0274078.	1.1	0
634	A replication-competent smallpox vaccine LC16m8Î”-based COVID-19 vaccine. Emerging Microbes and Infections, 2022, 11, 2359-2370.	3.0	5
635	Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. Frontiers in Immunology, 0, 13, .	2.2	7
636	When the Dust Has Settled: Calculation of Binding Affinities from First Principles for SARS-CoV-2 Variants with Quantitative Accuracy. Journal of Chemical Theory and Computation, 2022, 18, 5890-5900.	2.3	15
637	Health Risks During Ukrainian Humanitarian Crisis. Risk Management and Healthcare Policy, 0, Volume 15, 1775-1781.	1.2	5
638	SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria. PLoS ONE, 2022, 17, e0274509.	1.1	8
639	Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals. Microbiology Spectrum, 2022, 10, .	1.2	3
640	A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination. Viruses, 2022, 14, 2118.	1.5	1
642	The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. IScience, 2022, 25, 105016.	1.9	2
643	Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents. Vaccines, 2022, 10, 1474.	2.1	2
645	Identification and characterization of a novel cell binding and cross-reactive region on spike protein of SARS-CoV-2. Scientific Reports, 2022, 12, .	1.6	2
646	Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Emerging Microbes and Infections, 2022, 11, 2412-2422.	3.0	10
647	SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. Infectious Diseases, 0, , .	4.0	0
648	The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. Journal of Virology, 2022, 96, .	1.5	6

#	Article	IF	Citations
649	SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells. Microbiology Spectrum, 2022, 10, .	1.2	9
650	A novel cyclic Î³-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein. Cell Discovery, 2022, 8, .	3.1	13
651	Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters. Virologica Sinica, 2022, 37, 796-803.	1.2	4
652	A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. DARU, Journal of Pharmaceutical Sciences, 0, , .	0.9	5
653	Wastewater surveillance in smaller college communities may aid future public health initiatives. PLoS ONE, 2022, 17, e0270385.	1.1	3
654	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. Nature Communications, 2022, 13, .	5.8	11
655	Development of lab score system for predicting COVID-19 patient severity: A retrospective analysis. PLoS ONE, 2022, 17, e0273006.	1.1	3
656	Multiple introduced lineages and the single native lineage co-driving the four waves of the COVID-19 pandemic in West Africa. Frontiers in Public Health, 0, 10, .	1.3	4
657	SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant. Frontiers in Immunology, 0, 13, .	2.2	7
658	Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. Emerging Microbes and Infections, 2022, 11, 2275-2287.	3.0	48
659	How to cope with emerging viral diseases: lessons from South Korea's strategy for COVID-19, and collateral damage to cardiometabolic health. The Lancet Regional Health - Western Pacific, 2023, 30, 100581.	1.3	14
660	Long-Term Antibody Response to SARS-CoV-2 in Children. Journal of Clinical Immunology, 2023, 43, 46-56.	2.0	8
661	SARS-CoV-2 variants from COVID-19 positive cases in the Free State province, South Africa from July 2020 to December 2021. Frontiers in Virology, 0, 2, .	0.7	2
662	Phylodynamic analysis of SARS-CoV-2 spread in Rio de Janeiro, Brazil, highlights how metropolitan areas act as dispersal hubs for new variants. Microbial Genomics, 2022, 8, .	1.0	2
663	Delta variant: Partially sensitive to vaccination, but still worth global attention. Journal of Translational Internal Medicine, 2022, 10, 227-235.	1.0	2
665	Role for N -glycans and calnexin-calreticulin chaperones in SARS-CoV-2 Spike maturation and viral infectivity. Science Advances, 2022, 8, .	4.7	10
666	Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment. Applied Mathematical Modelling, 2023, 114, 447-465.	2.2	23
668	Impact of COVIDâ€19 vaccination on transmission risk of breakthrough infections: Lessons from adapted N95 mask sampling for emerging variants and interventions. Journal of Medical Virology, 2023, 95, .	2.5	2

#	Article	IF	Citations
669	A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analog inhibitors. Cell, 2022, 185, 4347-4360.e17.	13.5	21
670	BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. Cell Reports, 2022, 41, 111544.	2.9	17
671	The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. Science, 2022, 378, .	6.0	64
672	Milder outcomes of SARS-CoV-2 genetically confirmed reinfections compared to primary infections with the delta variant: A retrospective case-control study. Frontiers in Medicine, 0, 9, .	1.2	0
673	Recombinant Protein Micelles to Block Transduction by SARS-CoV-2 Pseudovirus. ACS Nano, 2022, 16, 17466-17477.	7.3	2
674	SARS-CoV-2 Omicron variant emerged under immune selection. Nature Microbiology, 2022, 7, 1756-1761.	5.9	21
678	Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options. Frontiers in Molecular Medicine, 0, 2, .	0.6	0
679	Genomic Analysis of SARS-CoV-2 Alpha, Beta and Delta Variants of Concern Uncovers Signatures of Neutral and Non-Neutral Evolution. Viruses, 2022, 14, 2375.	1.5	4
680	Spike protein mediated membrane fusion during SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2023, 95, .	2.5	15
681	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. Journal of Pharmaceutical Analysis, 2023, 13, 1-10.	2.4	1
682	Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike. Journal of Virology, 2022, 96, .	1.5	5
683	Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants. Journal of Infectious Diseases, 2023, 227, 344-352.	1.9	62
685	Variation analysis of SARS-CoV-2 complete sequences from Iran. Future Virology, 0, , .	0.9	0
687	SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. Nature Communications, 2022, 13, .	5.8	14
688	Local monitoring of SARS-CoV-2 variants in two large California counties in 2021. Scientific Reports, 2022, 12, .	1.6	0
689	Two Years of Genomic Surveillance in Belgium during the SARS-CoV-2 Pandemic to Attain Country-Wide Coverage and Monitor the Introduction and Spread of Emerging Variants. Viruses, 2022, 14, 2301.	1.5	6
690	Production and Purification of LTB-RBD: A Potential Antigen for Mucosal Vaccine Development against SARS-CoV-2. Vaccines, 2022, 10, 1759.	2.1	5
691	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science, 2022, 378, 619-627.	6.0	117

#	Article	IF	Citations
692	SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nature Reviews Microbiology, 2023, 21, 112-124.	13.6	128
693	Modeling COVID-19 Transmission Dynamics: A Bibliometric Review. International Journal of Environmental Research and Public Health, 2022, 19, 14143.	1.2	6
694	Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. Cell Host and Microbe, 2022, 30, 1745-1758.e7.	5.1	31
695	An experimental test of the nicotinic hypothesis of COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	5
696	Infection of the oral cavity with SARS-CoV-2 variants: Scope of salivary diagnostics. Frontiers in Oral Health, 0, 3, .	1.2	3
697	Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. , 2022, 19, 1302-1310.		17
699	Targeting an evolutionarily conserved â€œE-L-Lâ€•motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2. , 2022, 1, .		7
700	Smart healthcare: A prospective future medical approach for COVID-19. Journal of the Chinese Medical Association, 2023, 86, 138-146.	0.6	7
701	Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants. Molecular Therapy - Nucleic Acids, 2022, 30, 465-476.	2.3	6
702	Selective sweeps in SARS-CoV-2 variant competition. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	9
703	Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant. Emerging Infectious Diseases, 2022, 28, 2278-2288.	2.0	17
704	Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron. IScience, 2022, 25, 105316.	1.9	16
705	An electrochemical biosensor for SARS-CoV-2 detection via its papain-like cysteine protease and the protease inhibitor screening. Chemical Engineering Journal, 2023, 452, 139646.	6.6	23
706	The Impact and Progression of the COVID-19 Pandemic in Bulgaria in Its First Two Years. Vaccines, 2022, 10, 1901.	2.1	5
708	Whole-genome sequence analysis reveals the circulation of multiple SARS-CoV-2 variants of concern in Nairobi and neighboring counties, Kenya between March and July 2021. Virology Journal, 2022, 19, .	1.4	1
710	The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. International Journal of Molecular Sciences, 2022, 23, 14057.	1.8	4
712	Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B.1.1.7) and delta (B.1.617.2) variants. Scientific Reports, 2022, 12, .	1.6	16
713	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Science Immunology, 2022, 7, .	5.6	42

#	Article	IF	Citations
714	In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics. Viruses, 2022, 14, 2461.	1.5	6
715	Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques. Vaccine, 2022, 40, 7520-7525.	1.7	4
716	Rapid SARS-CoV-2 Variants Enzymatic Detection (SAVED) by CRISPR-Cas12a. Microbiology Spectrum, 2022, 10, .	1.2	7
717	SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression. PLoS Biology, 2022, 20, e3001871.	2.6	11
718	Seroepidemiological and genomic investigation of SARS-CoV-2 spread in North East region of India. Indian Journal of Medical Microbiology, 2022, , .	0.3	0
719	Structural analysis of a simplified model reproducing SARS-CoV-2 S RBD/ACE2 binding site. Heliyon, 2022, 8, e11568.	1.4	4
720	Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1. Viruses, 2022, 14, 2475.	1.5	0
721	ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner. Communications Biology, 2022, 5, .	2.0	13
722	Modelling COVID-19 vaccine breakthrough infections in highly vaccinated Israelâ€"The effects of waning immunity and third vaccination dose. PLOS Global Public Health, 2022, 2, e0001211.	0.5	11
723	Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with TÂcell immunity. IScience, 2022, 25, 105643.	1.9	5
724	Atlas of interactions between SARS-CoV-2 macromolecules and host proteins. , 2023, 2, 100068.		6
725	Stimulation of interferon-Î² responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists. IScience, 2023, 26, 105742.	1.9	4
726	Host microRNAs exhibit differential propensity to interact with SARS-CoV-2 and variants of concern. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166612.	1.8	2
727	SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor. Nano Today, 2023, 48, 101729.	6.2	14
728	Incidence of SARS-CoV-2 infection in hospital workers before and after vaccination programme in East Java, Indonesia â€“ aÂretrospective cohort study. , 2023, 10, 100130.		5
729	Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern. Vaccines, 2022, 10, 1962.	2.1	4
730	An overview of viral mutagenesis and the impact on pathogenesis of SARS-CoV-2 variants. Frontiers in Immunology, 0, 13, .	2.2	7
731	Predicting ICU Admissions for Hospitalized COVID-19 Patients withÂaÂFactor Graph-based Model. Studies in Computational Intelligence, 2023, , 245-256.	0.7	0

#	Article	IF	Citations
732	Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning. Science Advances, 2022, 8, .	4.7	16
734	SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. Biomolecules, 2022, 12, 1742.	1.8	6
735	Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. Frontiers in Medicine, 0, 9, .	1.2	2
736	As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?. Frontiers in Public Health, 0, 10, .	1.3	5
737	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions, 2022, 50, 1643-1658.	1.6	6
738	Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity. Biology, 2022, 11, 1786.	1.3	4
740	Coupling the Within-Host Process and Between-Host Transmission of COVID-19 Suggests Vaccination and School Closures are Critical. Bulletin of Mathematical Biology, 2023, 85, .	0.9	3
741	Risk of paediatric multisystem inflammatory syndrome (PIMS-TS) during the SARS-CoV-2 alpha and delta variant waves: National observational and modelling study, 2020â€“21, England. Frontiers in Pediatrics, 0, 10, .	0.9	4
743	In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant. Frontiers in Immunology, 0, 13, .	2.2	3
744	Omicron SARS-CoV-2 Variants in an In Silico Genomic Comparison Study with the Original Wuhan Strain and WHO-Recognized Variants of Concern. Polish Journal of Microbiology, 2022, 71, 577-587.	0.6	1
745	Bayesian Molecular Dating Analyses Combined with Mutational Profiling Suggest an Independent Origin and Evolution of SARS-CoV-2 Omicron BA.1 and BA.2 Sub-Lineages. Viruses, 2022, 14, 2764.	1.5	2
746	Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	11
747	Case series in Indonesia: B.1.617.2 (delta) variant of SARS-CoV-2 infection after a second dose of vaccine. World Journal of Clinical Cases, 0, 10, 13216-13226.	0.3	1
748	Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. Vaccines, 2022, 10, 2180.	2.1	16
750	Omicron infection increases IgG binding to spike protein of predecessor variants. Journal of Medical Virology, 2023, 95, .	2.5	5
753	Post COVID-19 irritable bowel syndrome. Gut, 2023, 72, 484-492.	6.1	17
754	Mutations in SARS-CoV-2 structural proteins: a global analysis. Virology Journal, 2022, 19, .	1.4	30
755	Recent developments in the immunopathology of <scp>COVID</scp>â€19. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 369-388.	2.7	33

#	Article	IF	Citations
757	Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis. Scientific Reports, 2022, 12, .	1.6	18
758	The Delta variant wave in Tunisia: Genetic diversity, spatio-temporal distribution and evidence of the spread of a divergent AY.122 sub-lineage. Frontiers in Public Health, 0, 10, .	1.3	3
759	The Potentials of Deep Learning Techniques for the Classification of SARS-CoV-2 Variants Based on Genomic Sequence Information. Lecture Notes in Networks and Systems, 2023, , 627-634.	0.5	0
760	Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster. Microbes and Infection, 2023, 25, 105101.	1.0	3
761	Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	1
763	Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. MBio, 2023, 14, .	1.8	14
765	Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. Frontiers in Immunology, 0, 13, .	2.2	2
766	Functionalized Fullerene for Inhibition of SARSâ€CoVâ€2 Variants. Small, 2023, 19, .	5.2	8
768	Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies. Pathogens, 2023, 12, 109.	1.2	2
769	SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India. Frontiers in Public Health, 0, 10, .	1.3	3
770	Comparative Analysis of the Diversity of SARS-CoV-2 Lines Circulating in Omsk Region in 2020â€“2022. Epidemiologiya I Vaktsinoprofilaktika, 2023, 21, 24-33.	0.2	2
772	Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. Cell Discovery, 2023, 9, .	3.1	11
773	SARS-CoV-2 delta (B.1.617.2) spike protein adjuvanted with Alum-3M-052 enhances antibody production and neutralization ability. Frontiers in Public Health, 0, 10, .	1.3	1
775	An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. IScience, 2023, 26, 105949.	1.9	1
776	SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nature Reviews Microbiology, 0, , .	13.6	160
777	The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries. Frontiers in Public Health, 0, 10, .	1.3	12
778	On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses. Viruses, 2023, 15, 70.	1.5	2
779	Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. Npj Vaccines, 2022, 7, .	2.9	19

#	Article	IF	Citations
780	Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients. Viruses, 2023, 15, 119.	1.5	6
781	Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. Medical Microbiology and Immunology, 2023, 212, 103-122.	2.6	18
782	The longitudinal evaluation of COVID-19 in pediatric patients and the impact of delta variant. Journal of Tropical Pediatrics, 2022, 69, .	0.7	0
783	Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies. Biomedicines, 2023, 11, 85.	1.4	5
784	Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. Vaccines, 2023, 11, 42.	2.1	5
785	Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection. Cell Reports Medicine, 2023, 4, 100943.	3.3	31
787	Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation. Epidemiology, 2023, 34, 365-375.	1.2	7
788	Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELDâ„¢) and BBV152 (COVAXINÂ®): a non-inferiority phase 4, participant and observer-blinded, randomised study. , 2023, 12, 100141.		14
789	Incipient Parallel Evolution of SARS-CoV-2 Deltacron Variant in South Brazil. Vaccines, 2023, 11, 212.	2.1	1
791	Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface. Scientific Reports, 2023, 13, .	1.6	15
793	SARS-CoV-2 evolution influences GBP and IFITM sensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	12
794	A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. Nature Materials, 0, , .	13.3	9
795	Coronavirus Immunotherapeutic Consortium Database. Database: the Journal of Biological Databases and Curation, 2023, 2023, .	1.4	4
796	Satisfaction of Polish pharmacists with completed training in the field of qualification and vaccination against COVID-19. Journal of Education, Health and Sport, 2023, 13, 90-97.	0.0	0
798	Characterization of a Vesicular Stomatitis Virus-Vectored Recombinant Virus Bearing Spike Protein of SARS-CoV-2 Delta Variant. Microorganisms, 2023, 11, 431.	1.6	1
799	Emergence and competition of virus variants in respiratory viral infections. Frontiers in Immunology, 0, 13, .	2.2	1
800	The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China. BMC Public Health, 2023, 23, .	1.2	1
801	SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?. Journal of Translational Medicine, 2023, 21, .	1.8	9

#	Article	IF	Citations
803	Rapid detection of intact SARS-CoV-2 using designer DNA Nets and a pocket-size smartphone-linked fluorimeter. Biosensors and Bioelectronics, 2023, 229, 115228.	5.3	0
804	Molecular determinants associated with temporal succession of SARS-CoV-2 variants in Uttar Pradesh, India. Frontiers in Microbiology, 0, 14, .	1.5	1
805	Histopathological Lung Findings in COVID-19 B.1.617.2 SARS-CoV-2 Delta Variant. Journal of Personalized Medicine, 2023, 13, 279.	1.1	3
806	Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. Chinese Medical Journal, 2023, 136, 24-33.	0.9	2
808	The Impact of SARS-CoV-2 Lineages (Variants) and COVID-19 Vaccination on the COVID-19 Epidemic in South Africa: Regression Study. Jmirx Med, 0, 4, e34598.	0.2	6
809	SARS-CoV-2 Variant-Specific mRNA Vaccine: Pros and Cons. Viral Immunology, 0, , .	0.6	0
810	Origin and evolution of SARS-CoV-2. European Physical Journal Plus, 2023, 138, .	1.2	16
811	Computational analysis of the sequence-structure relation in SARS-CoV-2 spike protein using protein contact networks. Scientific Reports, 2023, 13, .	1.6	5
812	Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps. Structure, 2023, 31, 253-264.e6.	1.6	3
813	Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19. Acta Pharmaceutica Sinica B, 2023, 13, 3638-3658.	5.7	2
814	Trend and Co-occurrence Network of COVID-19 Symptoms From Large-Scale Social Media Data: Infoveillance Study. Journal of Medical Internet Research, 0, 25, e45419.	2.1	1
815	Viral Lineages in the 2022 RSV Surge in the United States. New England Journal of Medicine, 2023, 388, 1335-1337.	13.9	24
816	Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine. International Journal of Molecular Sciences, 2023, 24, 4398.	1.8	0
817	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. International Journal of Molecular Sciences, 2023, 24, 4401.	1.8	4
818	Clinical features, management and outcomes of peritoneal dialysis patients during Delta and Omicron waves of COVID-19 infections. International Urology and Nephrology, 2023, 55, 2075-2081.	0.6	2
819	Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nature Methods, 2023, 20, 512-522.	9.0	111
820	BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. PLoS Pathogens, 2023, 19, e1011196.	2.1	6
821	SARS-CoV-2 molecular epidemiology in Slovenia, January to September 2021. Eurosurveillance, 2023, 28, .	3.9	1

#	Article	IF	Citations
822	Effectiveness of Inactivated Vaccine against SARS-CoV-2 Delta Variant Infection in Xiamen, Chinaâ€"A Test-Negative Case-Control Study. Vaccines, 2023, 11, 532.	2.1	0
823	Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19. BMC Medicine, 2023, 21, .	2.3	3
824	SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. Viruses, 2023, 15, 639.	1.5	1
825	Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study. Vaccines, 2023, 11, 566.	2.1	3
826	Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. International Immunopharmacology, 2023, 117, 109968.	1.7	17
827	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. TrAC - Trends in Analytical Chemistry, 2023, 161, 117000.	5.8	11
828	Effectiveness of mRNA and viralâ€vector vaccines in epidemic period led by different SARSâ€CoVâ€2 variants: A systematic review and metaâ€analysis. Journal of Medical Virology, 2023, 95, .	2.5	3
830	Phylogenetic Changes in SARS-CoV-2 Virus in Bosnian-Herzegovinian Population Over the Period of Two Years. Acta Informatica Medica, 2023, 31, 57.	0.5	0
831	Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. Nature Communications, 2023, 14, .	5.8	21
833	Conformational Behavior of SARS-Cov-2 Spike Protein Variants: Evolutionary Jumps in Sequence Reverberate in Structural Dynamic Differences. Journal of Chemical Theory and Computation, 2023, 19, 2120-2134.	2.3	2
834	Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China. ELife, 0, 12, .	2.8	5
835	An Adagio for Viruses, Played Out on Ancient DNA. Genome Biology and Evolution, 2023, 15, .	1.1	7
836	A k-mer based metaheuristic approach for detecting COVID-19 variants. DÃœMF MÃ¼hendislik Dergisi, 2023, 14, 17-26.	0.2	1
837	adaPop: Bayesian inference of dependent population dynamics in coalescent models. PLoS Computational Biology, 2023, 19, e1010897.	1.5	0
840	Organoids to Remodel SARS-CoV-2 Research: Updates, Limitations and Perspectives. , 2023, .		0
841	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. PLoS ONE, 2023, 18, e0283473.	1.1	2
842	COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray. Analytical Chemistry, 2023, 95, 5610-5617.	3.2	4
843	Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants. Genome Biology and Evolution, 2023, 15, .	1.1	1

#	Article	IF	Citations
844	The influence of single-point mutation D614G on the binding process between human angiotensin-converting enzyme 2 and the SARS-CoV-2 spike protein-an atomistic simulation study. RSC Advances, 2023, 13, 9800-9810.	1.7	0
845	Virus-Specific Stem Cell Memory CD8+ T Cells May Indicate a Long-Term Protection against Evolving SARS-CoV-2. Diagnostics, 2023, 13, 1280.	1.3	0
846	Different Variants of SARS-CoV-2: A Comprehensive Review on Mutation Patterns and Pathogenicity. Coronaviruses, 2023, 4, .	0.2	1
847	Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. EBioMedicine, 2023, 90, 104545.	2.7	17
848	Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. IScience, 2023, 26, 106540.	1.9	2
849	Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range. PLoS Pathogens, 2023, 19, e1011206.	2.1	8
850	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
851	Multiplex RT Real-Time PCR Based on Target Failure to Detect and Identify Different Variants of SARS-CoV-2: A Feasible Method That Can Be Applied in Clinical Laboratories. Diagnostics, 2023, 13, 1364.	1.3	1
852	Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. Viruses, 2023, 15, 944.	1.5	19
853	Genomic Surveillance of SARS-CoV-2 Variants in the Dominican Republic and Emergence of a Local Lineage. International Journal of Environmental Research and Public Health, 2023, 20, 5503.	1.2	2
854	Understanding COVID-19-related myocarditis: pathophysiology, diagnosis, and treatment strategies. Cardiology Plus, 0, Publish Ahead of Print, .	0.2	1
855	Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon, 2023, 9, e15587.	1.4	1
856	Mice Humanized for MHC and hACE2 with High Permissiveness to SARS-CoV-2 Omicron Replication. Microbes and Infection, 2023, , 105142.	1.0	0
918	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
936	Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. Chemical Society Reviews, 2023, 52, 6497-6553.	18.7	1
980	SARS-CoV-2 and innate immunity: the good, the bad, and the â€œgoldilocksâ€• , 2024, 21, 171-183.		4
995	Virus-Induced Cell Fusion and Syncytia Formation. Results and Problems in Cell Differentiation, 2024, , 283-318.	0.2	1
1003	Innovation-driven trend shaping COVID-19 vaccine development in China. Frontiers of Medicine, 2023, 17, 1096-1116.	1.5	0

#	Article	IF	Citations